NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Oxford Blood Group
    • Case Studies
    • PPIE Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Study develops radiotranscriptomic AI analysis to enable virtual heart biopsies

Study develops radiotranscriptomic AI analysis to enable virtual heart biopsies

5 September 2022 · Listed under Cardiovascular Medicine, COVID-19, Imaging

Oxford University researchers have found a new way of directly quantifying vascular inflammation in COVID-19 patients, in a study that could pave the way to more efficient trials of new treatments and identify patients who might be at risk of long-term complications. 

The study, which was supported by the NIHR Oxford Biomedical Research Centre (BRC), was published in the Lancet Digital Health. 

Professor Charalambos Antoniades, BHF Chair of Cardiovascular Medicine at the University’s Radcliffe Department of Medicine and lead author of the study, said: “We’ve developed a novel image analysis platform, which uses artificial intelligence to quantify cytokine-driven vascular inflammation from routine CT angiograms.”

CT angiograms combine a CT scan with an injection of a special dye to produce pictures of blood vessels and tissue structure in the heart. They are relatively non-invasive and routinely done in many hospitals. 

Professor Antoniades and his team used the data from CT angiograms to carry out ‘virtual biopsies’, by deriving a radiomic ‘signature’ from the angiogram images. They then used machine learning to train this signature against transcriptomic profiles (derived from RNA sequencing data) from tissue biopsies. 

This is therefore the first study to introduce a new radiotranscriptomics analysis pipeline., 

Using this method, the researchers developed C19-RS, a radiotranscriptomic signature of vascular cytokine-driven arterial inflammation.  

The team tested this new radiotranscriptomic signature with data from routine CT angiograms of patients with COVID-19, to find that cytokine-driven vascular inflammation predicts thrombosis and the likelihood of patients dying in hospital.

This method also identified patients who respond well to steroid treatment. 

Dr Christos Kotanidis, the first author of the paper, said: “Quantifying cytokine-induced vascular inflammation in patients with COVID-19 can therefore help clinicians in risk stratification, and potentially guide the deployment of specific anti-inflammatory treatments to those who need them.”

The new radiotranscriptomics platform also allows the development of customised imaging biomarkers of vascular inflammation, tailored to the type of inflammation of interest to clinicians and researchers, and the changes that it causes to the perivascular space around human arteries.

The research team therefore think that the method could also be used for other vascular inflammatory diseases – such as aortic aneurysms, carotid artery disease, or even autoimmune diseases like temporal arteritis – following appropriate independent validation and cost-effectiveness analyses. 

As well as the Oxford BRC, the study was funded by the Engineering and Physical Sciences Research Council, British Heart Foundation, Oxford BHF Centre of Research Excellence, Innovate UK and the Wellcome Trust. 

← Higher risk of blood clots in COVID-19 outpatients, largely reduced after vaccination
One in eight people have undiagnosed nighttime hypertension →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre